title: Strong emerging rationale for combining oncogene-targeted agents with immunotherapy.
abstract: In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy.
authors.affiliation: Department of Melanoma Medical Oncology; MD Anderson Cancer Center; Houston, TX, USA ; Immunology Program; Graduate School of Biomedical Science; University of Texas Health Science Center at Houston; Houston, TX USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Yang
authors.forename: Gregory
authors.initials: G
authors.lastname: Lizée
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
keywords: C-KIT mutant tumors; anti-OX40; dasatinib; immunotherapy; targeted therapy